Chiwala Gift, Kamng'ona Raphael, Kudowa Evaristar, Tembo Godwin, Mayuni Mphatso, Chimgoneko Lorensio, Kamanga Morrison, Thole Faith, Nthandira Tiyamike, Galafa Bridgette, Kadzanja Glory, Chikaonda Tarsizio, Ndaferankhande John, Chirwa Anthony, Nsomba Edna, Makhaza Lumbani, Sulani Innocent, Muyaya Alfred, Toto Neema, Henrion Marc Y R, Dula Dingase, Lipunga Gareth, Morton Ben, Banda Peter, Jambo Kondwani, Gordon Stephen B
Malawi Liverpool Wellcome Programme, P.O. Box 30096, Blantyre. Malawi.
Malawi Liverpool Wellcome Programme, P.O. Box 30096, Blantyre. Malawi.
Clin Immunol. 2025 Jul;276:110489. doi: 10.1016/j.clim.2025.110489. Epub 2025 Apr 1.
Mucosal inflammation is associated with increased nasal pneumococcal colonisation, but the specific mechanisms are not fully understood. We aimed to find innate immune factors associated with pneumococcal carriage using a controlled human infection model.
Healthy Malawian adults participating in a randomised trial of pneumococcal conjugate vaccine (PCV13) were inoculated with one of three doses of Streptococcus pneumoniae 6B. We categorised the participants into 4 pneumococcal carriage outcome groups - no carriage; natural carriage; experimental carriage; and dual carriage. We then measured neutrophil to lymphocyte ratio (NLR) in nasal mucosa and cytokine levels in nasal lining fluid at 7 days before and 2, 7 and 14 days after inoculation.
We found that 45 % of participants had no carriage, 35 % had natural carriage, 12 % experimental carriage and 8 % dual carriage. At 2- and 7-days post inoculation, all groups showed an increase in NLR compared to 7 days before inoculation, accompanied by small changes in cytokine levels. An early increase in NLR was associated with protection against experimental carriage while cytokines did not associate with carriage pattern.
Nasal inoculation with S. pneumoniae 6B induced mild, mucosal inflammation but established carriage was not pro-inflammatory. This suggests that nasal inoculation as a vaccine strategy could be asymptomatic.
黏膜炎症与鼻腔肺炎球菌定植增加有关,但具体机制尚未完全明确。我们旨在使用可控人类感染模型来寻找与肺炎球菌携带相关的固有免疫因子。
参与肺炎球菌结合疫苗(PCV13)随机试验的健康马拉维成年人接种三剂肺炎链球菌6B中的一剂。我们将参与者分为4个肺炎球菌携带结果组——无携带;自然携带;实验性携带;以及双重携带。然后我们在接种前7天以及接种后2天、7天和14天测量鼻黏膜中的中性粒细胞与淋巴细胞比率(NLR)以及鼻洗液中的细胞因子水平。
我们发现45%的参与者无携带,35%有自然携带,12%有实验性携带,8%有双重携带。接种后2天和7天,与接种前7天相比,所有组的NLR均升高,同时细胞因子水平有微小变化。NLR早期升高与预防实验性携带有关,而细胞因子与携带模式无关。
用肺炎链球菌6B进行鼻腔接种可诱发轻度黏膜炎症,但已确立的携带并非促炎性的。这表明鼻腔接种作为一种疫苗策略可能是无症状的。